In the brain, key focal points for control of metabolic function and feeding behavior are melanocortin receptors MC3R and MC4R. These receptors respond to two ligands, alpha-melanocyte stimulating hormone and Agouti-related protein (AgRP), which act in opposite ways to promote negative and positive energy balance, respectively. The goal of this program is to understand the molecular basis of MCR regulation. Work from the last funding period uncovered new mechanistic features of AgRP processing, solved the NMR structure of the homologous agouti signaling protein (ASIP) found in the skin, and identified 2-defensins, released by the immune system, as a new class of MCR ligands. The next phase of this research will build on these advances with the following four projects. 1) The AgRP N-terminal domain greatly inhibits its affinity for MCRs. NMR, pharmacology and collaborative in vivo studies, will be used to test the hypothesis that a partially conserved acidic domain docks to a C-terminal loop thus occluding receptor docking. 2) 2-Defensins are not homologous to AgRP or ASIP, but comparison of their respective structural features identifies specific loops that may target MCRs. Structure- function studies will uncover the structural basis for 2-defensin antagonism of MCRs. 3) Although published work identifies 2-defensin 3 as a ligand to MC1R and MC4R, preliminary results show that other defensins bind as well. A screen across the family of 2-defensins will be performed to identify additional MCR interactions, thus pointing to potential new 2-defensin functions. 4) 2-Defensins are challenging to fold in vitro, thus confounding important functional investigations. Human ASIP presented similar difficulties that were overcome by the PI's lab using protein engineering. Analogous strategies will be used with members of the 2-defensin family to advance the understanding of the defensin fold and to produce useful protein for pharmacological and structural studies.
Obesity is one of the greatest public health concerns facing Western society. The condition arises from an imbalance between energy intake and expenditure and contributes to diabetes, high blood pressure, high blood cholesterol, coronary artery disease, gallbladder disease, certain cancers and osteoarthritis. In the brain, the melanocortin system plays a central role in controlling feeding behavior and metabolic function. Melanocortin receptors are identified as prime therapeutic targets. This research program uses protein structure determination, protein engineering, pharmacology and screening to uncover the molecular details responsible for regulation of the melanocortin system.
|Nix, Matthew A; Kaelin, Christopher B; Palomino, Rafael et al. (2015) Electrostatic Similarity Analysis of Human Î²-Defensin Binding in the Melanocortin System. Biophys J 109:1946-58|
|Ghamari-Langroudi, Masoud; Digby, Gregory J; Sebag, Julien A et al. (2015) G-protein-independent coupling of MC4R to Kir7.1 in hypothalamic neurons. Nature 520:94-8|
|Nix, Matthew A; Kaelin, Christopher B; Ta, Tina et al. (2013) Molecular and functional analysis of human Î²-defensin 3 action at melanocortin receptors. Chem Biol 20:784-95|
|Huang, Zhi-ming; Chinen, Milka; Chang, Philip J et al. (2012) Targeting protein-trafficking pathways alters melanoma treatment sensitivity. Proc Natl Acad Sci U S A 109:553-8|
|Ersoy, Baran A; Pardo, Leonardo; Zhang, Sumei et al. (2012) Mechanism of N-terminal modulation of activity at the melanocortin-4 receptor GPCR. Nat Chem Biol 8:725-30|
|Madonna, Michael E; Schurdak, Jennifer; Yang, Ying-Kui et al. (2012) Agouti-related protein segments outside of the receptor binding core are required for enhanced short- and long-term feeding stimulation. ACS Chem Biol 7:395-402|
|Beaumont, Kimberley A; Smit, Darren J; Liu, Yan Yan et al. (2012) Melanocortin-1 receptor-mediated signalling pathways activated by NDP-MSH and HBD3 ligands. Pigment Cell Melanoma Res 25:370-4|
|Swope, Viki B; Jameson, Joshua A; McFarland, Kevin L et al. (2012) Defining MC1R regulation in human melanocytes by its agonist Ã½Ã½-melanocortin and antagonists agouti signaling protein and Ã½Ã½-defensin 3. J Invest Dermatol 132:2255-62|
|Beaumont, Kimberley A; Wong, Shu S; Ainger, Stephen A et al. (2011) Melanocortin MCâ‚ receptor in human genetics and model systems. Eur J Pharmacol 660:103-10|
|Patel, Mira P; Cribb Fabersunne, Camila S; Yang, Ying-Kui et al. (2010) Loop-swapped chimeras of the agouti-related protein and the agouti signaling protein identify contacts required for melanocortin 1 receptor selectivity and antagonism. J Mol Biol 404:45-55|
Showing the most recent 10 out of 26 publications